CareTalk: Healthcare. Unfiltered.

The episode is densely packed with technical and clinical insights about targeted radiotherapeutics, including detailed explanations of chelation chemistry, pharmacokinetics optimization, isotope properties (alpha vs. beta emitters), and clinical progression strategies. However, there is some throat-clearing and repetitive framing that reduces the density slightly - the host occasionally restates what was just said, and Babich occasionally circles back to concepts already explained.

“Trillium was a… something that bound to the tumor that was linked to a core hub, and that was then would have a, a payload... the third piece to that was something that would reversibly bind albumin, and we could fine-tune the structure of that, so we could generate for the same affinity for tumor and the same payload, we could keep changing the affinity for the blood”

“if you change the pharmacokinetics, the PK, the blood curve, and this is what we, we were observing, you could actually get more and more into the tumor”

Babich presents genuinely novel technical approaches (Trillium's three-part modular scaffold, macrochelation for actinium, PK manipulation for tumor uptake optimization) and shares first-hand observational work from exploratory INDs that drove unconventional compound selection. However, much of the framing - the three pillars of cancer treatment, the PSMA-based approach, the broader enthusiasm around radiotherapeutics - reflects consensus positions in the field rather than contrarian takes. The combinatorial strategy with FAP and stromal modulation is somewhat novel but not deeply developed in this conversation.

“we decided, so let's break this molecule into its component pieces. We had therefore the, it was a trifunctional compound, and we came up with the word Trillium based on the flower”

“This is not a therapy study... you could do a, um, a scan in a patient, then re-scan them again with another analog of the same type of compound, and then make your best decision based on the preliminary imaging data”

Babich is a 30+ year veteran of radiopharmaceuticals with deep clinical and R&D experience, now leading a company at the forefront of the field. He has direct involvement in early Pluvicto development and cites relationships with key opinion leaders (Oliver Sartor). His pedigree includes tenures at major institutions and successful track records (Molecular Insight acquisition, Lantheus partnerships). He is a practitioner-scientist actually building infrastructure and running trials, not a career podcast guest.

“I had - I was involved very early on in development of agents like Pluvicto, and we did the first therapy with our colleagues in Heidelberg many years ago now”

“I was very fortunate to have the a- in, the interaction and the experience, uh, to be where I am right now... on both continents of the US and, and Europe and, and, uh, in many institutions”

The episode includes specific drug names (Pluvicto, Lutathera, Xedera, Enhertu), real company examples (Novartis, BMS, Lilly, TerraPower Isotopes, Panterra, Niawave, NuSano, Lantheus), named targets (PSMA, FAP), concrete timelines (10-day half-life for actinium, 5-minute labeling at neutral pH, 24-hour uptake curves), and cited institutions (Cornell, Heidelberg, Tulane, Mayo). However, the conversation lacks specific clinical trial results, efficacy numbers, safety event rates, or cost data that would further strengthen specificity.

“actinium, uh, is a very large metal, and it is an alpha emitter... It has a 10-day half-life, and you know, alphas l- it just gives off many alpha particles”

“TerraPower Isotopes, which is a division of TerraPower, uh, out in, uh, the Northwest... NuSano is another company which is adjacent to our facility at, in Salt Lake City. They're gonna be coming online fairly s-shortly with a linear accelerator approach”

The host asks substantive follow-up questions (about Trillium differentiation, alpha vs. beta emitters, actinium supply, big pharma entry, future landscape) and does occasionally probe deeper. However, most questions are relatively soft, allowing Babich to deliver long expository monologues without pushback. There are few instances of genuine challenge, skepticism, or drilling into contradictions. The host occasionally makes jokes or meta-comments about audience appeal rather than pressing on technical or strategic tensions.

“Now, actinium, uh, is a very large metal... Let me go back a minute. So medical oncologists that are in the prostate cancer space have embraced Pluvicto, right?”

“Now, now let's switch a little bit and tell me about alpha emitters, beta emitters, and here how MacroPa fits in. Yeah, sure. I, I hesi- I hesitate to ask, but, uh, I think that's the other key platform”